EU Centrally Authorised Medicines (EMA marketing-authorisation holders)
Regulated market (ema centrally authorised medicines, ma holders). The Kin Score Market layer reads each provider in its market: who it integrates with, how deep those integrations go, and where the market publishes its own structure. Methodology.
Where this market publishes its structure
- EMA medicines report xlsx (ema.europa.eu/en/medicines/download-medicine-data -> medicines-output-medicines-report_en.xlsx), non-ATMP human + veterinary rows machine-readable, 2,368 rows / 714 holders; names only; 18 linked; one certified product per product type
- EMA medicines report, Advanced therapy = Yes rows machine-readable, already read by cell-gene-therapy; its EMA edges reused, not re-read
- EMA orphan designations report xlsx machine-readable, no sponsor column; unusable for participation (2026-10-22)
- EMA ISO IDMP / SPOR overview page not machine-readable: prose overview, no participant list (2026-10-22)
- SPOR OMS organisations (spor.ema.europa.eu/omswi/) not machine-readable: WAF 'Request Rejected' to a plain GET; not worked around (2026-10-22)
Own = declares at least one integration itself; covered = visible only because an aggregator, standards body, regulator or partner contract names it; distribution-only = listed only on cloud marketplaces it sells through, a channel reported beside, never counted as its own declared integrations; undeclared = nothing we can read, so no number; declares_compatibility = providers with a `compatible` shape vote, report only (kin, 2026-10-13): never counted as own, never in depth or position.
Taxonomy how this market maps onto apis.io
Derived 2026-10-23 from the 19 providers in this market we could resolve in the catalog. The percentage is the share of those providers carrying each one; it describes the market, not the tag or industry. Tag groups have no page of their own yet, so they are listed unlinked.
| Tags | Healthcare 84%, Pharmaceuticals 84%, Biotechnology 58%, Life Sciences 58%, Fortune 500 37%, Clinical Trials 26% |
|---|---|
| Tag groups | Healthcare 95% |
| Industries | Healthcare 89%, Pharmaceutical 89%, Biotechnology & Drug Discovery 63%, Life Sciences 58% |
share of resolved cohort carrying it; tags >=0.20 & >=3 members (max 12, junk dropped), tag_groups >=0.20 (cooccurrence, non-cross-cutting; max 8), industries >=0.20 (max 6), areas >=0.10 (max 6; areas are keyword-matched and sparse), capabilities L1 >=0.20 (max 8); derive-market-taxonomy.py
Leaders by position (provisional)
Provisional: grouped by position, depth compared within a position only. Distribution (cloud marketplaces) and iPaaS bridges are counted beside position, never inside it. Unknown-builder listings are left out of position shares and counted here.
regulated 9 · named in a regulator's register or partners' contracts
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| Viatris | 63.8 | 3 | 0 / 3 | 0 | 0 | 0 | contract 67%, standard 33% |
| Abbott Laboratories | 63.6 | 10 | 0 / 10 | 0 | 0 | 0 | contract 80%, standard 20% |
| Organon | 61.7 | 4 | 0 / 4 | 0 | 0 | 0 | contract 50%, standard 50% |
| AbbVie | 61.6 | 7 | 0 / 7 | 0 | 0 | 0 | contract 57%, standard 43% |
| Novo Nordisk | 59.9 | 6 | 0 / 6 | 0 | 0 | 0 | contract 50%, standard 50% |
| Eli Lilly | 58.5 | 10 | 0 / 10 | 0 | 0 | 0 | contract 50%, standard 50% |
| Insmed | 56.4 | 4 | 0 / 4 | 0 | 0 | 0 | contract 50%, standard 50% |
| Bayer | 53.5 | 7 | 0 / 7 | 0 | 1 | 0 | contract 43%, standard 43%, distribution 14% |
| Takeda Pharmaceutical Company | 22.7 thin | 1 | 0 / 1 | 0 | 0 | 0 | contract 100% |
standard 10 · listed by a voluntary standard's own directory
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | 63.3 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| Pfizer | 61.8 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| Autolus | 60.7 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Sanofi | 59.7 | 5 | 0 / 5 | 0 | 0 | 0 | contract 40%, standard 60% |
| Novartis | 59.3 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| AstraZeneca | 58.4 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Gilead Sciences | 57.8 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Merck | 57.8 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Biogen | 56.0 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| GSK | 55.0 | 5 | 0 / 5 | 0 | 0 | 0 | contract 20%, standard 80% |
Generated 2026-10-24 from API Evangelist's own files; nothing on this page is a model's judgement. Provisional and unweighted; not part of the Kin Score composite or agent readiness. Read the Market layer methodology. Disagree with an edge? Every edge cites its evidence and can be corrected through the normal correction path.